Treatment algorithms in stage IV melanoma

Keyphrases

• Advanced Melanoma 66%
• BRAF Inhibitor (BRAFi) 33%
• BRAF Wild-type 33%
• BRAF-mutant Melanoma 33%
• Chemotherapy 33%
• Conventional Chemotherapy 33%
• Current Therapeutics 33%
• Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) 33%
• Exon 11 33%
• Exon 13 33%
• Expert Forums 33%
• Ipilimumab 33%
• Kinase Inhibitor 33%
• KIT Inhibitors 66%
• Long-term Potential 33%
• Long-term Survival 33%
• Melanoma 33%
• Melanoma Patients 33%
• Molecular Classification 33%
• New Drugs 33%
• New Therapeutic Approaches 33%
• Participation in Clinical Trials 66%
• Previous Treatment 33%
• Salvage Therapy 33%
• Stage IV Melanoma 100%
• Subsequent Line 33%
• Therapeutic Algorithm 66%
• Therapy/immunotherapy 33%
• Trametinib 33%
• Treatment Algorithm 100%
• Treatment Choice 33%
• Treatment Goals 33%
• Treatment Lines 33%
• Treatment Modalities 33%
• Tumor 33%
• Tumor Genotyping 100%
• Tumor Load 33%
• Tumor Response 33%
• Vemurafenib 66%

Medicine and Dentistry

• Chemotherapy 33%
• Clinical Trial 33%
• Dabrafenib 16%
• Exon 16%
• Immunotherapy 16%
• Ipilimumab 16%
• Long Term Survival 16%
• Melanoma 100%
• Molecular Classification 16%
• Neoplasm 66%
• Phosphotransferase Inhibitor 16%
• Salvage Therapy 16%
• Treatment Modality 16%
• Tumor 16%
• Vemurafenib 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy Regimens 33%
• Clinical Trial 33%
• Cytotoxic T Lymphocyte Antigen 4 16%
• Dabrafenib 16%
• Immunotherapy 16%
• Ipilimumab 16%
• Long Term Survival 16%
• Melanoma 100%
• Neoplasm 66%
• Phosphotransferase Inhibitor 16%
• Vemurafenib 33%